A Single and Multiple Dose Study to Explore the Safety of JNJ-38224342 in Healthy Patients and Patients With Seasonal Allergies

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A single and multiple dose study to assess the safety of JNJ 38224342 compared to placebo in healthy volunteers and in volunteers with seasonal allergies.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Criteria

Inclusion Criteria:

• Non-smokers

• If male, willing to use an acceptable method of birth control for duration of study and for 90 days post study

• Females must be post menopausal, surgically sterilized and cannot be pregnant or lactating (all parts of study)

• Have a clinical history of allergic rhinitis during the ragweed pollen season and a positive skin test for ragweed allergy are required (for part 4 of study only)

Exclusion Criteria:

• Clinically significant medical illnesses, laboratory or ECG findings

• History of allergy to aspirin or nonsteroidal anti-inflammatory drugs

• history of alcohol or drug abuse within the last 5 years

• HIV or Hepatitis B or C positive

• Receipt of an investigational drug or use of an investigational medical device within the last month

• History of asthma or severe respiratory infection or disorder